<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">7V7JXkKDk4QZSzzCXkRZSGp</article-id>
      <article-id pub-id-type="other">00007</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010001500007</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09500507</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010005000111</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Disfun&#231;&#227;o renal moderada n&#227;o est&#225; associada a Troponina T elevada em s&#237;ndromes coronarianas agudas</article-title>
        <trans-title-group xml:lang="en">
          <trans-title>Moderate renal dysfunction is not associated with elevated Troponin T in acute coronary syndromes</trans-title>
        </trans-title-group>
        <trans-title-group xml:lang="es">
          <trans-title>Disfunci&#243;n renal moderada no est&#225; asociada a Troponina T elevada en s&#237;ndromes coronarias agudas</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Correia</surname>
            <given-names>Luis C. L.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barbosa</surname>
            <given-names>Carolina E.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cerqueira</surname>
            <given-names>Thais</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vasconcelos</surname>
            <given-names>Ana</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Merelles</surname>
            <given-names>Saulo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reis</surname>
            <given-names>Tiago</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lima</surname>
            <given-names>Jos&#233; C.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Esteves</surname>
            <given-names>J. P&#233;ricles</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Teixeira</surname>
            <given-names>Marcela S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state">Bahia</named-content>
        </addr-line>
        <institution content-type="orgname">Escola Bahiana de Medicina e Sa&#250;de P&#250;blica</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">Salvador</named-content>
          <named-content content-type="state">Bahia</named-content>
        </addr-line>
        <institution content-type="orgname">Hospital Portugu&#234;s da Bahia</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>10</month>
        <year>2010</year>
      </pub-date>
      <volume>95</volume>
      <issue>5</issue>
      <fpage>600</fpage>
      <lpage>605</lpage>
      <history>
        <date date-type="rev-recd">
          <day>16</day>
          <month>11</month>
          <year>2009</year>
        </date>
        <date date-type="received">
          <day>16</day>
          <month>07</month>
          <year>2009</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>12</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A interpreta&#231;&#227;o dos resultados de troponina em pacientes com s&#237;ndromes coronarianas agudas (SCA) e doen&#231;a renal &#233; dificultada pelo fato de que a disfun&#231;&#227;o renal aumenta os n&#237;veis de troponina, independente da necrose mioc&#225;rdica. Embora tenha sido demonstrado que a doen&#231;a renal em est&#225;gio terminal est&#225; associada com n&#237;veis elevados de troponina T card&#237;aca (TnT), ainda n&#227;o &#233; conhecido se esse biomarcador &#233; alterado por n&#237;veis menos graves de disfun&#231;&#227;o renal. OBJETIVO: Avaliar se disfun&#231;&#227;o renal moderada est&#225; associada com eleva&#231;&#227;o dos n&#237;veis de TnT em pacientes com SCA. M&#201;TODOS: Um total de 145 indiv&#237;duos com SCA e clearance de creatinina &gt; 30 ml/min foram estudados. O clearance de creatinina foi estimado atrav&#233;s da f&#243;rmula de Cockcroft-Gault e a TnT foi medida na admiss&#227;o hospitalar. Disfun&#231;&#227;o renal moderada foi definida como clearance de creatinina de 30-59 ml/min e TnT positiva como n&#237;veis &gt; 0,01 ug/l. RESULTADOS: Nenhuma correla&#231;&#227;o foi observada entre o clearance de creatinina e TnT (r = - 0,06, P=0,45). Os n&#237;veis de TnT foram similares entre indiv&#237;duos no primeiro (mediana=0,05 ug/l), segundo (mediana=0 ug/l), terceiro (mediana=0,07 ug/l) e quarto quartis (mediana=0 ug/l) de clearance de creatinina - P=0,63. De forma similar, n&#227;o houve diferen&#231;a nos valores de troponina entre indiv&#237;duos com disfun&#231;&#227;o renal moderada (mediana=0,02 ug/l) e indiv&#237;duos com fun&#231;&#227;o renal normal/quase normal (mediana=0,03 ug/l) - P=0.63. A preval&#234;ncia de TnT positiva foi similar entre indiv&#237;duos com disfun&#231;&#227;o renal moderada e fun&#231;&#227;o renal normal/quase normal (55% vs 52%, P=0,65). CONCLUS&#195;O: Disfun&#231;&#227;o renal moderada n&#227;o est&#225; associada com eleva&#231;&#227;o dos n&#237;veis de TnT em pacientes com SCA. (Arq Bras Cardiol 2010; 95(5): 600-605)</p>
      </abstract>
      <trans-abstract xml:lang="en">
        <p>BACKGROUND: Interpretation of troponin results in patients with acute coronary syndromes (ACS) and renal disease is confused by the fact that renal dysfunction increases troponin levels, regardless of myocardial necrosis. Although it has been demonstrated that end-stage renal disease is associated with elevated cardiac troponin T (cTnT) levels, it is not known whether this biomarker is altered by less than severe degrees of renal impairment. OBJECTIVE: To evaluate whether moderate renal dysfunction is associated with cTnT elevation in patients with ACS. METHODS: One hundred, forty-five individuals with ACS and creatinine clearance &gt; 30 ml/min were studied. Creatinine clearance was estimated by the Cockcroft-Gault formula and cTnT was measured at hospital admission. Moderate renal dysfunction was defined as a creatinine clearance of 30-59 ml/min and positive cTnT as levels &gt; 0.01 ug/l. RESULTS: No correlation was observed between creatinine clearance and cTnT (r = - 0.06, P=0.45). The levels of cTnT were similar among individuals in the first (median=0.05 ug/l), second (median=0 ug/l), third (median=0.07 ug/l) and fourth quartiles (median=0 ug/l) of creatinine clearance - P=0.63. Similarly, there was no difference in troponin values between individuals with moderate renal dysfunction (median=0.02 ug/l) and individuals with normal/near normal function (median=0.03 ug/l) - P=0.63. The prevalence of positive cTnT was similar between individuals with moderate renal dysfunction and normal/near normal renal function (55% vs 52%, P=0.65). CONCLUSION: Moderate renal dysfunction is not associated with cTnT elevation in patients with ACS. (Arq Bras Cardiol 2010; 95(5): 600-605)</p>
      </trans-abstract>
      <trans-abstract xml:lang="es">
        <p>FUNDAMENTO: La interpretaci&#243;n de los resultados de troponina en pacientes con s&#237;ndromes coronarias agudas (SCA) y enfermedad renal es dificultada debido al hecho de que la disfunci&#243;n renal aumenta los niveles de troponina, independientemente de la necrosis mioc&#225;rdica. Aunque se haya sido evidenciada la enfermedad renal en fase terminal est&#225; asociada con niveles elevados de troponina T card&#237;aca (TnT), a&#250;n no se conoce si este biomarcador es alterado por niveles menos severos de disfunci&#243;n renal. OBJETIVOS: Evaluar si la disfunci&#243;n renal moderada est&#225; asociada con la elevaci&#243;n de los niveles de TnT en pacientes con SCA. M&#201;TODOS: Un total de 145 individuos con SCA y clearance de creatinina &gt; 30 ml/min fueron estudiados. El clearance de creatinina se estim&#243; a trav&#233;s de la f&#243;rmula de Cockcroft-Gault y la TnT se midi&#243; en la admisi&#243;n hospitalaria. Disfunci&#243;n renal moderada se defini&#243; como clearance de creatinina de 30-59 ml/min y TnT positiva como niveles &gt; 0,01 ug/L. RESULTADOS: No se observ&#243; alguna correlaci&#243;n entre el clearance de creatinina y TnT (r = - 0,06, P=0,45). Los niveles de TnT fueron similares entre individuos en el primero (mediana=0,05 ug/L), segundo (mediana=0 ug/L), tercero (mediana=0,07 ug/L) y cuarto cuartiles (mediana=0 ug/L) de clearance de creatinina - P=0,63. De forma similar, no hubo diferencia en los valores de troponina entre individuos con disfunci&#243;n renal moderada (mediana=0,02 ug/L) y individuos con funci&#243;n renal normal/casi normal (mediana=0,03 ug/L) - P=0.63. La prevalencia de TnT positiva fue similar entre individuos con disfunci&#243;n renal moderada y funci&#243;n renal normal/casi normal (55% vs 52%, P=0,65). CONCLUSI&#211;N: Disfunci&#243;n renal moderada no est&#225; asociada con la elevaci&#243;n de los niveles de TnT en pacientes con SCA. (Arq Bras Cardiol 2010;95(5):600-605)</p>
      </trans-abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Troponina T</kwd>
        <kwd>doen&#231;a renal</kwd>
        <kwd>doen&#231;a das coron&#225;rias</kwd>
      </kwd-group>
      <kwd-group xml:lang="en" kwd-group-type="author-generated">
        <kwd>Troponin T</kwd>
        <kwd>kidney disease</kwd>
        <kwd>coronary disease</kwd>
      </kwd-group>
      <kwd-group xml:lang="es" kwd-group-type="author-generated">
        <kwd>Troponina T</kwd>
        <kwd>enfermedad renal</kwd>
        <kwd>enfermedad de las coronarias</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>27</day>
        <month>08</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> CORONARIOPATIA AGUDA</p>
    <p>
      <bold>Disfun&#231;&#227;o renal moderada n&#227;o est&#225; associada a Troponina T elevada em s&#237;ndromes coronarianas agudas</bold>
    </p>
    <p>
      <bold>Luis C. L. Correia; Carolina E. Barbosa; Thais Cerqueira; Ana Vasconcelos; Saulo Merelles; Tiago Reis; Jos&#233; C. Lima; J. P&#233;ricles Esteves; Marcela S. Teixeira</bold>
    </p>
    <p>Escola Bahiana de Medicina, Hospital Portugu&#234;s, Salvador, BA - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A interpreta&#231;&#227;o dos resultados de troponina em pacientes com s&#237;ndromes coronarianas agudas (SCA) e doen&#231;a renal &#233; dificultada pelo fato de que a disfun&#231;&#227;o renal aumenta os n&#237;veis de troponina, independente da necrose mioc&#225;rdica. Embora tenha sido demonstrado que a doen&#231;a renal em est&#225;gio terminal est&#225; associada com n&#237;veis elevados de troponina T card&#237;aca (TnT), ainda n&#227;o &#233; conhecido se esse biomarcador &#233; alterado por n&#237;veis menos graves de disfun&#231;&#227;o renal. </p>
    <p><bold>OBJETIVO:</bold> Avaliar se disfun&#231;&#227;o renal moderada est&#225; associada com eleva&#231;&#227;o dos n&#237;veis de TnT em pacientes com SCA. </p>
    <p><bold>M&#201;TODOS:</bold> Um total de 145 indiv&#237;duos com SCA e clearance de creatinina <underline>&gt;</underline> 30 ml/min foram estudados. O clearance de creatinina foi estimado atrav&#233;s da f&#243;rmula de Cockcroft-Gault e a TnT foi medida na admiss&#227;o hospitalar. Disfun&#231;&#227;o renal moderada foi definida como clearance de creatinina de 30-59 ml/min e TnT positiva como n&#237;veis <underline>&gt;</underline> 0,01 ug/l. </p>
    <p><bold>RESULTADOS:</bold> Nenhuma correla&#231;&#227;o foi observada entre o clearance de creatinina e TnT (r = - 0,06, P=0,45). Os n&#237;veis de TnT foram similares entre indiv&#237;duos no primeiro (mediana=0,05 ug/l), segundo (mediana=0 ug/l), terceiro (mediana=0,07 ug/l) e quarto quartis (mediana=0 ug/l) de clearance de creatinina - P=0,63. De forma similar, n&#227;o houve diferen&#231;a nos valores de troponina entre indiv&#237;duos com disfun&#231;&#227;o renal moderada (mediana=0,02 ug/l) e indiv&#237;duos com fun&#231;&#227;o renal normal/quase normal (mediana=0,03 ug/l) - P=0.63. A preval&#234;ncia de TnT positiva foi similar entre indiv&#237;duos com disfun&#231;&#227;o renal moderada e fun&#231;&#227;o renal normal/quase normal (55% <italic>vs</italic> 52%, P=0,65). </p>
    <p><bold>CONCLUS&#195;O:</bold> Disfun&#231;&#227;o renal moderada n&#227;o est&#225; associada com eleva&#231;&#227;o dos n&#237;veis de TnT em pacientes com SCA. (Arq Bras Cardiol 2010; 95(5): 600-605)</p>
    <p><bold>Palavras-chave:</bold> Troponina T/an&#225;lise, doen&#231;a renal, doen&#231;a das coron&#225;rias.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>N&#237;veis elevados de troponina T (TnT) est&#227;o comumente elevados em pacientes com doen&#231;a renal em est&#225;gio terminal, independente da presen&#231;a de necrose mioc&#225;rdica<sup>1-7</sup>. Este fen&#244;meno representa um fator confundidor para a interpreta&#231;&#227;o dos n&#237;veis de TnT na presen&#231;a de s&#237;ndromes coronarianas agudas (SCA) em indiv&#237;duos com disfun&#231;&#227;o renal. Disfun&#231;&#227;o renal moderada est&#225; presente em 40% dos indiv&#237;duos com SCA<sup>8</sup>. Diferentemente da doen&#231;a renal em est&#225;gio terminal, os dados s&#227;o limitados e conflitantes em rela&#231;&#227;o &#224; eleva&#231;&#227;o dos n&#237;veis de TnT nesse n&#237;vel de doen&#231;a renal. Abbas e cols.<sup>7</sup> reportaram TnT positiva em 11% de 56 indiv&#237;duos est&#225;veis com disfun&#231;&#227;o renal moderada, mas Chew<sup>9</sup> n&#227;o encontrou uma correla&#231;&#227;o entre a fun&#231;&#227;o renal e os n&#237;veis de TnT em pacientes com SCA e insufici&#234;ncia renal.</p>
    <p>Se disfun&#231;&#227;o renal leve a moderada influencia os n&#237;veis de TnT, algum tipo de correla&#231;&#227;o ou associa&#231;&#227;o categ&#243;rica &#233; esperada entre a fun&#231;&#227;o renal e n&#237;veis de TnT, neste tipo de paciente. A fim de testar essa hip&#243;tese, estudamos 145 pacientes admitidos com SCA e fun&#231;&#227;o renal normal ou alterada de forma leve a moderada. An&#225;lise de correla&#231;&#227;o entre o clearance de creatinina e n&#237;veis de TnT foi realizada e as taxas de TnT positiva foram comparadas entre os grupos definidos pelo n&#237;vel de fun&#231;&#227;o renal.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>
      <bold>Sele&#231;&#227;o da amostra</bold>
    </p>
    <p>Pacientes consecutivos admitidos na Unidade Coronariana de nosso hospital com SCA e com pelo menos 18 anos de idade foram considerados candidatos para participar de um registro prospectivo local. Os crit&#233;rios de inclus&#227;o para o registro foram definidos como dor tor&#225;cica ou equivalente dentro de 24 horas da admiss&#227;o e pelo menos uma das seguintes caracter&#237;sticas: 1) altera&#231;&#245;es isqu&#234;micas eletrocardiogr&#225;ficas, definidas como invers&#227;o de onda T din&#226;mica, infradesnivelamento de segmento ST ou supradesnivelamento de segmento ST; 2) marcadores s&#233;ricos de necrose mioc&#225;rdica acima do limite superior de normalidade; 3) documenta&#231;&#227;o pr&#233;via de doen&#231;a arterial coronariana. Todos os participantes forneceram seu consentimento livre e informado e o protocolo de estudo foi aprovado pelo comit&#234; de &#233;tica em pesquisa com seres humanos da institui&#231;&#227;o.</p>
    <p>No total, 500 pacientes foram inclu&#237;dos no registro no per&#237;odo entre 1999 e 2007. Nesse banco de dados, 151 indiv&#237;duos tinham resultados dispon&#237;veis de troponina e creatinina s&#233;ricas. Desse grupo, 145 indiv&#237;duos com clearance de creatinina <underline>&gt;</underline> 30 ml/min (fun&#231;&#227;o renal normal, disfun&#231;&#227;o renal leve ou moderada) foram inclu&#237;dos no presente estudo. Assim, como definido pela popula&#231;&#227;o alvo desse estudo, os indiv&#237;duos com disfun&#231;&#227;o renal grave foram exclu&#237;dos da an&#225;lise.</p>
    <p>
      <bold>Protocolo de estudo e defini&#231;&#245;es</bold>
    </p>
    <p>Amostras de sangue para determina&#231;&#227;o de n&#237;veis de TnT e creatinina foram obtidas na apresenta&#231;&#227;o inicial ao pronto-socorro. A troponina card&#237;aca T foi medida atrav&#233;s de imunoensaio por quimioluminesc&#234;ncia (Roche Diagnostics Corporation, Indianapolis, Indiana, EUA) e troponina positiva foi definida como valores <underline>&gt;</underline> 0,01 ug/l, que &#233; o limite inferior de detec&#231;&#227;o do m&#233;todo e representa valores acima do percentil 99 da popula&#231;&#227;o em geral<sup>10</sup>. A creatinina foi medida pelo m&#233;todo colorim&#233;trico de Jaff&#233; (Dade-Behring, Newark, Delaware, EUA)<sup>11</sup>. O clearance de creatinina foi calculado atrav&#233;s da f&#243;rmula de Cockcroft-Gault, definida como [(140 - idade) x peso kg) / (72 x creatinina s&#233;rica mg/dl)] x (0,85 se pertencente ao sexo feminino), na qual o peso corporal magro foi utilizado ao inv&#233;s do peso corporal total<sup>8,12</sup>. O peso corporal magro foi calculado usando a f&#243;rmula [0,9 x (altura cm - 152)] + (50 se pertencente ao sexo masculino, 45,5 se feminino)<sup>13</sup>. Disfun&#231;&#227;o renal moderada foi definida como clearance de creatinina entre 30 e 59 ml/min<sup>14</sup>.</p>
    <p>
      <bold>An&#225;lise de dados</bold>
    </p>
    <p>Devido &#224; distribui&#231;&#227;o n&#227;o-normal dos n&#237;veis de TnT, essa vari&#225;vel foi descrita como mediana e intervalo interquartil, enquanto testes estat&#237;sticos n&#227;o-param&#233;tricos foram os preferidos. O clearance de creatinina, com distribui&#231;&#227;o normal, foi descrito como m&#233;dia &#177; desvio-padr&#227;o. Como forma de avaliar a influ&#234;ncia da fun&#231;&#227;o renal nos n&#237;veis de TnT, a hip&#243;tese de uma associa&#231;&#227;o linear entre o clearance de creatinina e n&#237;veis de TnT foi testada pelo coeficiente de correla&#231;&#227;o de Spearman em toda a amostra. A fim de avaliar se uma influ&#234;ncia exagerada de valores extremos era respons&#225;vel pelos resultados, uma an&#225;lise secund&#225;ria foi realizada ap&#243;s a exclus&#227;o de valores extremos (outliers), definidos como res&#237;duo estudantizado maior do que tr&#234;s desvios-padr&#227;o da m&#233;dia. Al&#233;m disso, os valores de TnT foram comparados entre quartis de clearance de creatinina pelo teste de Kruskal-Wallis e entre indiv&#237;duos dicotomizados por disfun&#231;&#227;o renal moderada (clearance de creatinina = 30 - 59 ml/min) ou fun&#231;&#227;o renal normal/disfun&#231;&#227;o renal leve (<underline>&gt;</underline> 60 ml/min) pelo teste de Mann-Whitney. Finalmente, a frequ&#234;ncia de pacientes com TnT positiva foi comparada entre quartis de clearance de creatinina e entre indiv&#237;duos dicotomizados por disfun&#231;&#227;o renal moderada, utilizando o Teste Qui-quadrado. O <italic>software</italic> SPSS vers&#227;o 10.0 foi utilizado em todas as an&#225;lises de dados e um valor de P &lt; 0,05 foi considerado estatisticamente significante.</p>
    <p>
      <bold>C&#225;lculo do poder estat&#237;stico</bold>
    </p>
    <p>Considerando que uma amostra de conveni&#234;ncia de 145 pacientes foi estudada, o poder estat&#237;stico e n&#227;o o tamanho da amostra foi calculado: levando-se em conta o desvio-padr&#227;o observado de 2,69 ug/l para a troponina e 25 ml/min para o clearance de creatinina, o n&#250;mero real de pacientes forneceu 98% de poder estat&#237;stico para detectar um coeficiente de correla&#231;&#227;o significante de pelo menos 0,3, com um n&#237;vel de signific&#226;ncia de 0,05. Para este c&#225;lculo foi utilizado o <italic>software</italic> RegPower, Vers&#227;o 4.0 (PM Galingher &amp; DS Sharp 1993-2001, PEPI).</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>
      <bold>Caracter&#237;sticas da popula&#231;&#227;o</bold>
    </p>
    <p>Cento e quarenta e cinco pacientes foram estudados, com idade m&#233;dia de 67 &#177; 11 anos, dos quais 57% eram do sexo masculino; 17% foram definidos na admiss&#227;o como apresentando infarto agudo do mioc&#225;rdio com supradesnivelamento do segmento ST (IAMCSST) e o restante foi caracterizado como SCA sem supradesnivelamento do segmento ST (SCASSST). O tempo entre o in&#237;cio dos sintomas e a determina&#231;&#227;o laboratorial apresentou uma mediana de 3,9 horas (intervalo interquartil = 1,5 - 12), indicando uma determina&#231;&#227;o relativamente precoce dos marcadores de necrose mioc&#225;rdica. Os n&#237;veis de troponina T card&#237;aca apresentaram uma mediana de 0,02 ug/l (0,01 - 0,34 ug/l) e 53% dos indiv&#237;duos apresentavam TnT positiva (&gt; 0,01 ug/l). O clearance de creatinina apresentou m&#233;dia de 68 &#177; 25 ml/min e 46% apresentavam disfun&#231;&#227;o renal moderada (30 - 59 ml/min), 36% disfun&#231;&#227;o renal leve (60 - 89 ml/min) e 18% fun&#231;&#227;o renal normal. As caracter&#237;sticas cl&#237;nicas s&#227;o mostradas na <xref ref-type="table" rid="tab1">Tabela 1</xref> e o tratamento durante a hospitaliza&#231;&#227;o na <xref ref-type="table" rid="tab2">Tabela 2</xref>.</p>
    <table-wrap id="tab1">
      <graphic xlink:href="1678-4170-abc-95-05-0600-00111-gt01.jpg"/></table-wrap>
    <table-wrap id="tab2">
      <graphic xlink:href="1678-4170-abc-95-05-0600-00111-gt02.jpg"/></table-wrap>
    <p>
      <bold>Rela&#231;&#227;o entre fun&#231;&#227;o renal e troponina card&#237;aca T</bold>
    </p>
    <p>Nenhuma correla&#231;&#227;o foi observada entre o clearance de creatinina e n&#237;veis de TnT (r = - 0,06, P = 0,45), indicando aus&#234;ncia de influ&#234;ncia da fun&#231;&#227;o renal sobre a variabilidade da TnT - <xref ref-type="fig" rid="a07fig01m">Figura 1</xref>, Painel A. esse achado permaneceu inalterado ap&#243;s a exclus&#227;o dos valores extremos da curva (outliers) (N = 138, r = - 0,05, P = 0,55). A aus&#234;ncia de correla&#231;&#227;o entre o clearance de creatinina e os n&#237;veis de TnT tamb&#233;m foi observada (r = - 0,06, P = 0,63) quando somente indiv&#237;duos com TnT detect&#225;vel (&gt; 0 ug/l) foram avaliados - <xref ref-type="fig" rid="a07fig01m">Figura 1</xref>, Painel B. O primeiro, segundo, terceiro e quarto quartis de clearance de creatinina foram distribu&#237;dos como &lt; 51 ml/min, 51-64 ml/min, 65-83 ml/min e &gt; 83 ml/min, respectivamente. Os n&#237;veis de troponina T foram similares entre indiv&#237;duos no primeiro (mediana = 0,05 ug/l; intervalo interquartil = 0 - 0,37 ug/l), segundo (mediana = 0 ug/l; intervalo interquartil = 0 - 0.22 ug/l), terceiro (mediana = 0.07 ug/l; intervalo interquartil = 0 - 0.32 ug/l) e quarto quartis (mediana = 0 ug/l; varia&#231;&#227;o interquartil = 0 - 0.58 ug/l) de clearance de creatinina - P = 0,63 - <xref ref-type="fig" rid="a07fig02m">Figure 2</xref>, Painel A. Similarmente, indiv&#237;duos com disfun&#231;&#227;o renal moderada (clearance de creatinina = 30 - 59 ml/min) e aqueles com fun&#231;&#227;o normal/quase normal (<underline>&gt;</underline> 60 ml/min) tinham n&#237;veis de TnT similares (0,02 ug/l; 0 - 0,36 ug/l <italic>vs</italic> 0,03 ug/l; 0 - 0,33 ug/l) - P = 0,63 - <xref ref-type="fig" rid="a07fig02m">Figura 2</xref>, Painel B. A preval&#234;ncia de TnT positiva foi similar entre indiv&#237;duos no primeiro, segundo, terceiro e quarto quartil de clearance (58% <italic>vs</italic> 47% <italic>vs</italic> 62% <italic>vs</italic> 44%, respectivamente, P = 0.36) e entre indiv&#237;duos com disfun&#231;&#227;o renal moderada e fun&#231;&#227;o renal normal/quase normal (55% <italic>vs</italic> 52%, P = 0,65) - <xref ref-type="fig" rid="a07fig03m">Figure 3</xref>.</p>
    <p content-type="asset">
      <fig id="a07fig01m">
        <graphic xlink:href="1678-4170-abc-95-05-0600-00111-gf01.jpg"/></fig>
    </p>
    <p content-type="asset">
      <fig id="a07fig02m">
        <graphic xlink:href="1678-4170-abc-95-05-0600-00111-gf02.jpg"/></fig>
    </p>
    <p content-type="asset">
      <fig id="a07fig03m">
        <graphic xlink:href="1678-4170-abc-95-05-0600-00111-gf03.jpg"/></fig>
    </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>O presente estudo indica que a fun&#231;&#227;o renal n&#227;o influencia os n&#237;veis de TnT na admiss&#227;o hospitalar em indiv&#237;duos com SCA, variando de fun&#231;&#227;o renal normal a disfun&#231;&#227;o renal moderada. Essa observa&#231;&#227;o foi consistentemente reproduzida atrav&#233;s de diferentes formas de an&#225;lise de dados: correla&#231;&#227;o entre TnT e clearance de creatinina, compara&#231;&#227;o de TnT entre grupos definidos pelos n&#237;veis de clearance e compara&#231;&#227;o da frequ&#234;ncia de TnT positiva entre esses grupos.</p>
    <p>A aus&#234;ncia de correla&#231;&#227;o linear com um poder estat&#237;stico de 98% fornece evid&#234;ncia contra a influ&#234;ncia da disfun&#231;&#227;o renal leve a moderada sobre os n&#237;veis de TnT em pacientes com SCA. Entretanto, ela n&#227;o exclui uma rela&#231;&#227;o n&#227;o-linear. Para resolver essa quest&#227;o, os n&#237;veis de TnT foram comparados entre quartis de clearance de creatinina e nenhuma diferen&#231;a foi observada, mesmo assim. Al&#233;m disso, a TnT foi analisada como vari&#225;vel dicot&#244;mica (positiva ou negativa) e a frequ&#234;ncia de TnT positiva foi similar entre os grupos de diferentes n&#237;veis de fun&#231;&#227;o renal, de um extremo da fun&#231;&#227;o renal normal ao outro extremo da disfun&#231;&#227;o moderada. N&#227;o avaliamos mensura&#231;&#245;es seriadas de troponina, mas &#233; improv&#225;vel que essa abordagem mostre resultados diferentes, pois a eleva&#231;&#227;o da troponina devido &#224; disfun&#231;&#227;o renal &#233; um fen&#244;meno cr&#244;nico e a determina&#231;&#227;o da primeira amostra deve ser suficiente para avaliar esse achado.</p>
    <p>Cinquenta e tr&#234;s por cento de nossa amostra apresentavam n&#237;veis detect&#225;veis de TnT (<underline>&gt;</underline> 0.01 ug/l), o que corresponde a valores &gt; percentil 99<sup>10</sup>. No presente estudo, nossa inten&#231;&#227;o n&#227;o foi estabelecer a causa exata da eleva&#231;&#227;o da TnT e nossa conclus&#227;o concentra-se na interfer&#234;ncia da fun&#231;&#227;o renal sobre a troponina. Mas podemos especular que, considerando que a popula&#231;&#227;o estudada era composta de indiv&#237;duos com SCA, a probabilidade pr&#233;-teste de infarto do mioc&#225;rdio era alta. Essa probabilidade pr&#233;-teste, junto com nossas informa&#231;&#245;es sobre a aus&#234;ncia de influ&#234;ncia da fun&#231;&#227;o renal sobre a troponina, fortemente sugere que o dano mioc&#225;rdico isqu&#234;mico foi a causa da eleva&#231;&#227;o da TnT.</p>
    <p>O mecanismo exato atrav&#233;s do qual a disfun&#231;&#227;o renal aumenta os n&#237;veis de TnT permanece uma quest&#227;o a ser definida. Em indiv&#237;duos saud&#225;veis, ensaios de alta sensibilidade s&#227;o capazes de detectar quantidades muito pequenas de TnT s&#233;rica, indicando que a microperda cont&#237;nua de cardiomi&#243;citos &#233; normal<sup>15</sup>. Essas mol&#233;culas de TnT s&#227;o fragmentadas a fim de serem eliminadas pelos rins. Com base em nossos achados, podemos especular que a disfun&#231;&#227;o renal moderada n&#227;o &#233; suficiente para promover o ac&#250;mulo dos fragmentos de troponina.</p>
    <p>As limita&#231;&#245;es do estudo devem ser apontadas. Primeiro, como n&#227;o inclu&#237;mos indiv&#237;duos com clearance de creatinina &lt; 30 ml/min, nossos achados n&#227;o podem ser extrapolados para pacientes n&#227;o submetidos a di&#225;lise com disfun&#231;&#227;o renal grave. Em nossa amostra populacional original, tais pacientes foram escassos e nenhuma conclus&#227;o p&#244;de ser obtida em rela&#231;&#227;o a esse n&#237;vel de fun&#231;&#227;o renal. Assim, n&#227;o inclu&#237;mos esses pacientes e escolhemos nos concentrar na varia&#231;&#227;o de fun&#231;&#227;o renal normal a disfun&#231;&#227;o renal moderada. Segundo, nossa amostra n&#227;o &#233; grande o suficiente para excluir totalmente uma associa&#231;&#227;o quando o clearance de creatinina fica pr&#243;ximo de 30 ml/min. Por exemplo, somente 15 pacientes apresentavam um clearance entre 30 e 40 ml/min. Terceiro, n&#227;o t&#237;nhamos dados sobre as determina&#231;&#245;es da TnT no seguimento. Se fosse o caso, a normaliza&#231;&#227;o tardia dos n&#237;veis de TnT sugeririam que os casos de TnT positiva representavam infarto do mioc&#225;rdio.</p>
    <p>A utilidade dos resultados do presente estudo em rela&#231;&#227;o &#224; interpreta&#231;&#227;o dos n&#237;veis de cTnT em pacientes com SCA devem ser enfatizados. Na presen&#231;a de doen&#231;a renal, o n&#237;vel de disfun&#231;&#227;o deve ser avaliado. Se a disfun&#231;&#227;o n&#227;o for grave, uma eleva&#231;&#227;o nos n&#237;veis de cTnT n&#227;o deve ser atribu&#237;da &#224; doen&#231;a renal e a interpreta&#231;&#227;o desses valores deve ser feita independentemente da presen&#231;a de dano renal. Em conclus&#227;o, a disfun&#231;&#227;o renal moderada n&#227;o est&#225; associada &#224; eleva&#231;&#227;o nos n&#237;veis de cTnT em pacientes com SCA.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Luis C. L. Correia </p>
        <p> Av. Princesa Leopoldina, 19/402 - Gra&#231;a </p>
        <p> 40150-080 - Salvador, BA - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="lccorreia@terra.com.br">lccorreia@terra.com.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 16/07/09; revisado recebido em 16/11/09; aceito em 28/12/09.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Donnino MW, Karriem-Norwood V, Rivers EP, Gupta A, Nguyen HB, Jacobsen G, et al. Prevalence of elevated troponin I in end-stage renal disease patients receiving hemodialysis. Acad Emerg Med. 2004; 11 (9): 979-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of elevated troponin I in end-stage renal disease patients receiving hemodialysis</article-title>
          <source>Acad Emerg Med</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>979</fpage>
          <lpage>81</lpage>
          <issue>9</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Donnino</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Karriem-Norwood</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Rivers</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Gabr AE, Ibrahim IA, Aloulou SM, Al Alfi MA, Al Abdlrahim KA. Cardiac troponin T and end stage renal disease. Saudi Med J. 2004; 25 (8): 1015-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac troponin T and end stage renal disease</article-title>
          <source>Saudi Med J</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1015</fpage>
          <lpage>9</lpage>
          <issue>8</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gabr</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Ibrahim</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Aloulou</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Al Alfi</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Al Abdlrahim</surname>
              <given-names>KA.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Wayand D, Baum H, Schatzle G, Scharf J, Neumeier D. Cardiac troponin T and I in end-stage renal failure. Clin Chem. 2000; 46 (9): 1345-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac troponin T and I in end-stage renal failure</article-title>
          <source>Clin Chem</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1345</fpage>
          <lpage>50</lpage>
          <issue>9</issue>
          <volume>46</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wayand</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Baum</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Schatzle</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Scharf</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Neumeier</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. McNeil AR, Marshall M, Ellis CJ, Hawkins RC. Why is troponin T increased in the serum of patients with end-stage renal disease? Clin Chem. 1998; 44 (11): 2377-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Why is troponin T increased in the serum of patients with end-stage renal disease?</article-title>
          <source>Clin Chem</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>2377</fpage>
          <lpage>8</lpage>
          <issue>11</issue>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>McNeil</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Hawkins</surname>
              <given-names>RC.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Ooi DS, House AA. Cardiac troponin T in hemodialyzed patients. Clin Chem. 1998; 44 (7): 1410-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac troponin T in hemodialyzed patients</article-title>
          <source>Clin Chem</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1410</fpage>
          <lpage>6</lpage>
          <issue>7</issue>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ooi</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>House</surname>
              <given-names>AA.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Katus HA, Haller C, Muller-Bardorff M, Scheffold T, Remppis A. Cardiac troponin T in end-stage renal disease patients undergoing chronic maintenance hemodialysis. Clin Chem. 1995; 41: 1201-1203.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac troponin T in end-stage renal disease patients undergoing chronic maintenance hemodialysis</article-title>
          <source>Clin Chem</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>1201</fpage>
          <lpage>1203</lpage>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Katus</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Haller</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Muller-Bardorff</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Scheffold</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Remppis</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Abbas NA, John RI, Webb MC, Kempson ME, Potter AN, Price CP, et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. Clin Chem. 2005; 51 (11): 2059-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac troponins and renal function in nondialysis patients with chronic kidney disease</article-title>
          <source>Clin Chem</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>2059</fpage>
          <lpage>66</lpage>
          <issue>11</issue>
          <volume>51</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Abbas</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>John</surname>
              <given-names>RI</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Kempson</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Potter</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>CP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Melloni C, Peterson ED, Chen AY, Szczech LA, Newby LK, Harrington RA, et al. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2008; 51 (10): 991-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>991</fpage>
          <lpage>6</lpage>
          <issue>10</issue>
          <volume>51</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Melloni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Szczech</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Newby</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>Harrington</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Chew HC. Cardiac troponin T in acute coronary syndrome with renal insufficiency. Asian Cardiovasc Thorac Ann. 2008; 16 (4): 284-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac troponin T in acute coronary syndrome with renal insufficiency</article-title>
          <source>Asian Cardiovasc Thorac Ann</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>284</fpage>
          <lpage>7</lpage>
          <issue>4</issue>
          <volume>16</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chew</surname>
              <given-names>HC.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Apple FS, Quist HE, Doyle PJ, Otto AP, Murakami MM. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology Consensus Recommendations. Clin Chem. 2003; 49 (8): 1331-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology Consensus Recommendations</article-title>
          <source>Clin Chem</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1331</fpage>
          <lpage>6</lpage>
          <issue>8</issue>
          <volume>49</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Apple</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Quist</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Doyle</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Otto</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Murakami</surname>
              <given-names>MM.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Chromy V, Rozkosna K, Sedlak P. Determination of serum creatinine by Jaffe method and how to calibrate to eliminate matrix interference problems. Clin Chem Lab Med. 2008; 46 (8): 1127-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Determination of serum creatinine by Jaffe method and how to calibrate to eliminate matrix interference problems</article-title>
          <source>Clin Chem Lab Med</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1127</fpage>
          <lpage>33</lpage>
          <issue>8</issue>
          <volume>46</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chromy</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Rozkosna</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sedlak</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Lim WH, Lim EM, McDonald S. Lean body mass-adjusted Cockcroft and Gault formula improves the estimation of glomerular filtration rate in subjects with normal-range serum creatinine. Nephrology (Carlton ). 2006; 11 (3): 250-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Lean body mass-adjusted Cockcroft and Gault formula improves the estimation of glomerular filtration rate in subjects with normal-range serum creatinine</article-title>
          <source>Nephrology</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>250</fpage>
          <lpage>6</lpage>
          <issue>3</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lim</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993; 189 (3): 847-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction</article-title>
          <source>Radiology</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>847</fpage>
          <lpage>50</lpage>
          <issue>3</issue>
          <volume>189</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zasadny</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Wahl</surname>
              <given-names>RL.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003; 139 (2): 137-47.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification</article-title>
          <source>Ann Intern Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>137</fpage>
          <lpage>47</lpage>
          <issue>2</issue>
          <volume>139</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Levey</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Coresh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Balk</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kausz</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Levin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Steffes</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Missov ED, De Marco T. Clinical insights on the use of highly sensitive cardiac troponin assays. Clin Chim Acta. 1999; 284 (2): 175-85.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical insights on the use of highly sensitive cardiac troponin assays</article-title>
          <source>Clin Chim Acta</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>175</fpage>
          <lpage>85</lpage>
          <issue>2</issue>
          <volume>284</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Missov</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>De Marco</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
